Aristotle University Of Thessaloniki (AUTH)
Αξιολόγηση της αποτελεσματικότητας και της ασφάλειας της χορήγησης υδροξυουρίας στη λειτουργία των οργάνων παιδιών και νεαρών ενηλίκων με δρεπανοκυτταρική νόσο
Abstract
dc:descriptionSickle cell disease (SCD) is a multisystem disease which is characterized by phenotypic diversity. Hydroxyurea is a myelosuppresive cytostatic drug that has been used, during recent years, in the treatment of children with severe SCD. However, the role of hydroxyurea on early organ damage, when administered early in life, is not clear. The aim of the present study was to evaluate the safety and efficacy of hydroxyurea in children and young adults with SCD, and to investigate the effects of hydroxyurea on spleen, renal, brain, pulmonary and heart function, as well as on ocular manifestations. Twelve patients with SCD (11 with sickle/beta thalassemia and one with sickle cell anemia), aged 3.5-18 years, have completed the study period. Hydroxyurea was given for 3 years and for that time period clinical and laboratory evaluation of the patients was performed. Haematological and immune parameters, as well as coagulation system parameters and adhesion molecules were measured. Moreover, liver/spleen scintigraphy was performed and Howell-Jolly bodies were assessed. For renal function, a 24-hour urine specimen was collected, b2-microglobulin was measured and renal ultrasound was performed. Brain MRI/MRA, transcranial Doppler (TCD) and neuropsychological testing were performed at entry and study closure. Additionally, patients underwent spirometry, echocardiogram, electrocardiography and ocular examination. Testing was performed at entry and study closure. With regards to results, a reduction in pain crises and rate of hospitalizations was noted. None of the patients presented with severe clinical events related to the disease during the study period. With regards to haematological parameters, Hb concentration, HbF levels and RBC indices significantly increased. Furthermore, a significant decrease in the reticulocyte count, white blood cells and platelets count, as well as total bilirubin level was noted. With regard to the rest laboratory testing, the changes observed were within the normal range for patients' age. At study exit, there was a mild improvement on splenic function in only one non-splenectomized patient, with preservation of splenic function in the rest of patients. Significantly change was observed in eGFR. 41.7% of patients had impaired glomerular function with proteinuria or microalbuminuria, but these findings were resolved at study exit. TCD revealed that all patients, except one, had normal blood flow velocity. Findings on brain MRI/MRA were normal. Overall, an improvement on intelligence score was detected; nevertheless, those levels did not reach statistically significant levels. Concerning lung function, 2 patients had a restrictive pattern, while at the end of the study the measured lung volumes at pulmonary respiratory testing remained stable. Cardiological testing did not reveal any pathological finding at entry and study closure. With regard to ocular manifestations, 25% of patients had retinal vascular wall thickening and lumen narrowing at study exit. With regards to adverse events during the study period, mild haematologic toxicity, transient, short-term and dose-dependable was noted in 33.3% of patients. In conclusion, the present study evaluated the safety and efficacy of hydroxyurea treatment in children and young adults with SCD, the majority of them had sickle/beta-thalassemia. The study demonstrated that hydroxyurea treatment is well tolerated, with mild side effects, transient and dose-dependable. Hydroxyurea treatment improves the examined hematologic and haemolysis parameters, as well as clinical events. Moreover, our study indicates that hydroxyurea has beneficial effect on preservation or improvement of splenic function and reverse of renal glomerular dysfunction, contributes to maintenance of normal CNS findings and overall improvement of intelligence score, as well as to preservation of stable respiratory and cardiac function. Our study results are particularly encouraging, as hydroxyurea seems to have a protective role on organ damage in this patient group.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadopoulou, Eleni
- Παπαδοπούλου, Ελένη
Subjects
dc:subject × 16- Δρεπανοκυτταρική νόσος
- Yδροξυουρία
- Aγγειο - αποφρακτική κρίση
- Nεφρική λειτουργία
- Aγγειακό εγκεφαλικό έμφρακτο
- Σπληνική λειτουργία
- Sickle cell disease
- Ηydroxyurea
- Vaso - occlusive crisis
- Renal function
- Stroke
- Splenic function
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43962